melanoma/구역질

Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases, including infectious disease and cancer. ZADAXIN® brand Ta1 is a synthetic version currently approved for use in 37 countries; in

The standard procedure for initial diagnosis recommends the realization of laparoscopy first for all suspicious advanced ovarian carcinoma. This procedure should able to confirm histo-logical diagnosis and to describe the all abdominal extension of the disease. For advanced stages, complete primary

Vemurafenib is an anti-cancer treatment indicated as monotherapy in the treatment of adult patients with non-resectable or metastatic melanoma carrying a BRAF V600 mutation. Cobimetinib is indicated in combination with Vemurafenib in the treatment of adult patients with non-resectable or metastatic

Rationale: Current seasonal influenza vaccines mainly induce immune responses against viral membrane glycoproteins. These proteins, however, undergo continuous mutations by a process called antigenic drift. To prevent immune escape, annual vaccination with the latest predicted viral strains is

Inclusion criteria: 1. Males and females ≥ 20 years of age 2. ECOG performance status of 0-1 3. Histologically or cytologically verified non-squamous NSCLC 4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with

This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. The FDA (the U.S.

This is a Phase 2B double-blind placebo-controlled crossover study evaluating the efficacy of intravenous fosaprepitant for chemotherapy-induced nausea and vomiting in patients undergoing high-dose interleukin-2 (HD IL-2) therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course)

Study Groups: If you are found to be eligible and decide to take part, you will be assigned to a study group based on when you join this study. Up to 8 groups of 3-6 participants will be enrolled in this study. The dose of vemurafenib and the doses of carboplatin and paclitaxel you receive will

Rationale for treatment of uveal melanoma with sorafenib Improved understanding of the molecular pathogenesis of cancers has led to a new generation of therapeutic agents that interfere with a specific pathway critical in tumor development or progression. Although no specific genes have been linked

Methods Thirty patients (ASA status 1-2) in the age group 50 - 75 years, undergoing elective radical retropubic prostatectomy would be included in this pilot study. The exact type of cancer, its staging, degree of spread to proximal or distant sites and the pathologic type of cancer would be

The Study Drug TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing, which may cause them to die. Study Groups: Patient will be assigned to a study group based on when they join this study. Up to 4 groups of 3-6 participants will be enrolled in the Phase I

(177)Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms First Annual Report on protocol IND# 78,256 at RITA Foundation in collaboration with Excel diagnostics and Nuclear Oncology center and Baylor College of Medicine Protocol number 78,256 calls for

Study Drugs: Oblimersen is designed to stop the body from making a protein that makes melanoma cells resistant to chemotherapy drugs. This may make carboplatin and/or paclitaxel more effective. Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may

The ability to control melanoma depends on how well your immune system recognizes and then attacks cancer cells. Researchers want to use ipilimumab to try to trigger your immune system response, while temozolomide is designed to damage the cancer cells themselves. Study Drugs: Ipilimumab is designed